MARATTO

article · Parasites & Vectors

Evolving patterns of antimalarial drug resistance markers in symptomatic infections in Kenya, 2013–2022

Abstract

Our findings reveal no WHO-validated k13 mutations up until 2022 and confirm previous findings of a reduction in the Pfcrt resistance genotypes over time. This study underscores the importance of continued molecular surveillance and suggests that resistance may evolve through different pathways in East compared with West Africa and Southeast Asia.

Research topics

  • Malaria Research and Control
  • Pharmaceutical Quality and Counterfeiting
  • Tuberculosis Research and Epidemiology

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1186/s13071-026-07280-w

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.